Skip to main content
ZBIO
NASDAQ Life Sciences

Director Lu Hongbo Buys $1.5M in Zenas BioPharma Public Offering, Signaling Confidence

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$21.9
Mkt Cap
$1.121B
52W Low
$6.11
52W High
$44.6
52W Position info
258% above low
Off High info
51% below high
Rel. Volume info
2.6× avg
Market data snapshot near publication time

ZBIO has more than doubled off its 52-week low of $6.11 on elevated volume (2.6× avg).

Summary

Director Lu Hongbo purchased $1.5 million worth of Zenas BioPharma common stock at the offering price of $20.00 per share, participating in the company's recent public offering.


Key Events · Ownership and Investor Activity · ZBIO

  • Director Participates in Public Offering

    Director Lu Hongbo acquired 75,000 shares of common stock for $1,500,000 at a price of $20.00 per share, as part of the company's recent underwritten public offering.

  • Vote of Confidence

    The purchase signals strong insider confidence, especially given the recent dilutive public offering and the stock's prior reaction to the pricing.

  • Part of Broader Accumulation

    This transaction adds to a net accumulation of over $2.1 million in open market purchases by insiders over the last 90 days.


Analysis · ZBIO · Life Sciences

This significant purchase by Director Lu Hongbo, totaling $1.5 million, demonstrates a strong vote of confidence in Zenas BioPharma, particularly as it occurred within the recently completed public offering. The company recently raised $300 million through concurrent offerings of common stock and convertible senior notes, which typically causes dilution and can pressure the stock price. An insider's decision to invest a substantial amount at the offering price, especially after the stock experienced a significant drop following the offering announcement, suggests a belief in the company's long-term prospects and the strategic use of the raised capital. This purchase contributes to a pattern of insider accumulation observed over the last 90 days.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ZBIO was trading at $21.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $6.11 to $44.60. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ZBIO - Latest Insights

ZBIO
Nov 05, 2026, 7:19 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $28.46
Real-time Price: $25.48 info
Change: -$2.98 (-10%) info
Market Cap: $1.728B info
ZBIO
Nov 05, 2026, 7:00 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $28.46
Real-time Price: $25.48 info
Change: -$2.98 (-10%) info
Market Cap: $1.728B info
ZBIO
Oct 13, 2026, 6:01 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $26.40
Real-time Price: $25.48 info
Change: -$0.920 (-3%) info
Market Cap: $1.728B info
ZBIO
Aug 19, 2026, 4:15 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $31.04
Real-time Price: $25.48 info
Change: -$5.56 (-18%) info
Market Cap: $1.728B info
ZBIO
Aug 13, 2026, 7:15 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $31.30
Real-time Price: $25.48 info
Change: -$5.82 (-19%) info
Market Cap: $1.728B info